Access Denied? The Unintended Consequences of Pending Drug Pricing Rules.
PMPRB
access
clinical trials
development
funding
oncology
outcomes
pharmacotherapy
research
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
02 04 2022
02 04 2022
Historique:
received:
02
03
2022
revised:
28
03
2022
accepted:
31
03
2022
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
The government of Canada now plans to bring into force new federal drug pricing regulations on 1 July 2022. We do not take issue with the goal of medication affordability, which is vital in healthcare the world over. Our concern is that the new guidelines are being implemented without due consideration for three major unintended consequences: regulatory changes will lower the number of clinical trials for new medications in Canada, fewer clinical trials will mean lower research and development investments, and changes will reduce patients' access to new medications. Access to effective medications is a cornerstone of healthcare for Canadian patients. As physicians, our duty to patient care demands that we tell the government to protect the right of Canadians to timely access to life-changing medicines.
Identifiants
pubmed: 35448178
pii: curroncol29040204
doi: 10.3390/curroncol29040204
pmc: PMC9025245
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2504-2508Références
Curr Oncol. 2016 Oct;23(5):e454-e460
pubmed: 27803605
Oncologist. 2020 Jan;25(1):e130-e137
pubmed: 31506392
Eur J Health Econ. 2020 Feb;21(1):129-151
pubmed: 31583483